Details for New Drug Application (NDA): 205981
✉ Email this page to a colleague
The generic ingredient in SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
Summary for 205981
| Tradename: | SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE |
| Applicant: | Mylan |
| Ingredient: | metformin hydrochloride; saxagliptin hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 205981
| Mechanism of Action | Dipeptidyl Peptidase 4 Inhibitors |
Suppliers and Packaging for NDA: 205981
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE | metformin hydrochloride; saxagliptin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205981 | ANDA | Mylan Pharmaceuticals Inc. | 0378-8175 | 0378-8175-93 | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0378-8175-93) |
| SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE | metformin hydrochloride; saxagliptin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205981 | ANDA | Mylan Pharmaceuticals Inc. | 0378-8176 | 0378-8176-91 | 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0378-8176-91) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 500MG;EQ 5MG BASE | ||||
| Approval Date: | Jul 31, 2023 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 1GM;EQ 2.5MG BASE | ||||
| Approval Date: | Jul 31, 2023 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 1GM;EQ 5MG BASE | ||||
| Approval Date: | Jul 31, 2023 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
